Jorge Conde

Ben Horowitz, co-founder of Andreessen Horowitz and author of 'The Hard Thing About Hard Things,' joins Jorge Conde, a general partner focusing on bio and health investments. They delve into the difference between wartime and peacetime CEOs and the unique leadership challenges they face. The duo also explores how company culture is crucial, particularly during scaling, and shares insights on navigating the intricate landscape of healthcare startups versus established firms. Plus, they discuss the evolving role of AI in business strategy.

Julie Yoo, a general partner at Andreessen Horowitz with expertise in miracle drugs, discusses the transformative potential of GLP-1 therapies for obesity and diabetes, emphasizing access and affordability challenges. Jorge Conde dives into programmable medicine, highlighting innovations in gene and cell therapies aimed at curing diseases. Anjney Midha focuses on AI interpretability, advocating for clarity in AI decision-making processes, especially in critical fields like healthcare. Together, they explore how these big ideas could revolutionize medicine and technology in 2024.

Jorge Conde and Julie Yoo discuss the unique challenges of building a software company in healthcare, including regulations, market dynamics, and barriers to entry. They also explore the importance of balancing software and human services, data analysis, timing, achieving product-market fit, and navigating regulatory issues and incumbents in the industry.

Explore the past and future of cancer treatment with guests Gary Reedy, CEO of the American Cancer Society, Jonathan Lim, CEO of Erasca, and Jorge Conde, a16z general partner. Topics include the history of cancer treatment, the importance of screening and early detection, future therapies, and preventing cancer.

Marc Andreessen and Jorge Conde discuss the impact of COVID-19 on society and healthcare, including the need for innovation, a pandemic warning system, and measuring output. They explore the similarities between bio-pharma and venture capital, the importance of effective vaccines and telemedicine, and the urgency of rapid building and increased manufacturing capacity for a better future.